Breaking News Instant updates and real-time market news.

LEN

Lennar

, LPCN

Lipocine

$4.02

0.15 (3.88%)

09:23
06/20/17
06/20
09:23
06/20/17
09:23

On The Fly: Pre-market Movers

HIGHER: Lennar (LEN), up 3.6% after reporting quarterly results... Lipocine (LPCN), up 28.9% after announcing that LPCN 1021 achieved its primary endpoints in dosing studies... PAREXEL (PRXL), up 3.8% following an announcement that it will be acquired by Pamplona Capital Management for $88.10 per share. LOWER: Chipotle (CMG), down 4% after reaffirming and clarifying its second quarter and fiscal 2017 guidance... Fidus Investment (FDUS), down 3.2% after its 1.75M share Spot Secondary priced at $16.80... ADP (ADP), down 2% after being downgraded to Neutral from Conviction Buy at Goldman Sachs.

LEN

Lennar

LPCN

Lipocine

$4.02

0.15 (3.88%)

PRXL

Parexel

$83.92

0.42 (0.50%)

CMG

Chipotle

FDUS

Fidus Investment

$17.25

0.17 (1.00%)

ADP

ADP

$104.11

0.62 (0.60%)

  • 20

    Jun

  • 26

    Jun

  • 27

    Jul

  • 20

    Jun

LEN Lennar

05/16/17
MZHO
05/16/17
INITIATION
Target $59
MZHO
Buy
Lennar initiated with a Buy at Mizuho
Mizuho analyst Haendel St. Juste initiated Lennar with a Buy and a $59 price target.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
Barclays sees additiona near-term upside for builders
Barclays analyst Michael Dahl says his firm's February survey indicates "strong" early spring demand for U.S. homebuilders. Upcoming catalysts for the group will likely be positive, Dahl tells investors in a research note. The analyst sees "modest" further near-term upside for builder stocks despite the recent rallies. His Overweight rated names are PulteGroup (PHM), Lennar (LEN) and TRI Pointe (TPH). Dahl also believes D.R. Horton (DHI) is well positioned to capture incremental demand. He raised his price target for the shares to $34 from $30 but keeps an Equal Weight rating due to valuation.
03/22/17
RBCM
03/22/17
NO CHANGE
RBCM
Lennar shares should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall says that Lennar reported "solid" Q1 results. He blames the stock's weakness on "reduced profitability due to higher costs for land and construction coupled with one-time expenses associated with the acquisition of WCI Communities (WCIC)." However, since Lennar reiterated its fiscal 2017 margin guidance and made upbeat comments about its outlook, the weakness was "unwarranted," according to Wetenhall. He raised his price target on the shares to $60 from $53 and keeps an Outperform rating on the stock.
04/13/17
RAJA
04/13/17
NO CHANGE
Target $60
RAJA
Strong Buy
Lennar added to 'Analyst Current Favorites' at Raymond James
Raymond James analyst Buck Horne added Lennar to the '"Analyst Current Favorites" list and raised its price target to $60, based on last week's S-11 filing from from Five Point Holdings which increases his sum-of-the-parts valuation for the company. Horne now seesnew evidence to suggest that his prior estimates regarding the value of Lennar's equity stake in Five Point was likely too conservative, at $5-6/share previously, versus $9+/share now, due to a larger than expected 45% equity interest in FPH and greater clarity around total entitlements and transaction activity. The analyst rates Lennar a Strong Buy.
LPCN Lipocine
$4.02

0.15 (3.88%)

06/20/17
ADAM
06/20/17
NO CHANGE
Target $11
ADAM
Buy
Lipocine data sets path toward FDA submission, says Canaccord
Canaccord analyst Dewey Steadman noted Lipocine reported positive top-line data for its dosing validation and dosing flexibility studies, which were required for the resubmission of its oral testosterone NDA. The analyst sees a resubmission in Q3 and believes the company has sufficient capital to meet near-term needs while the company plans to partner the drug. Steadman reiterated his Buy rating and raised his price target to $11 from $10 on Lipocine shares.
02/21/17
ROTH
02/21/17
NO CHANGE
Target $38
ROTH
Buy
Lipocine price target raised to $38 from $30 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Lipocine to $38 from $30 following clarity on LPCN-1107's pivotal trial design. The analyst reiterates a Buy rating on the shares.
12/20/16
ADAM
12/20/16
INITIATION
Target $15
ADAM
Buy
Lipocine assumed with a Buy at Canaccord
Canaccord analyst Dewey Steadman assumed Lipocine with Buy and $15 price target citing its status as one of the leading companies developing oral testosterone replacement therapies to treat hypogonadism.
10/11/16
ADAM
10/11/16
NO CHANGE
Target $15
ADAM
Buy
Lipocine price target raised to $15 from $6 at Canaccord
Canaccord analyst John Newman raised his price target on Lipocine to $15 from $6 as he believes its oral testosterone product has better safety and convenience versus currently marketed gels and injectables. The analyst sees rapid market share gains and a 20% market share by 2024. Newman reiterated his Buy rating on Lipocine shares.
PRXL Parexel
$83.92

0.42 (0.50%)

06/20/17
RAJA
06/20/17
UPGRADE
RAJA
Market Perform
Parexel upgraded to Market Perform from Underperform at Raymond James
Raymond James analyst Michael Baker upgraded Parexl to Market Perform following the acquisition by Pamplona for $88.10 per share and said he does not expect a higher offer.
05/23/17
GSCO
05/23/17
UPGRADE
Target $77
GSCO
Neutral
Parexel upgraded to Neutral from Sell at Goldman Sachs
Goldman analyst Robert Jones upgraded Parexel to Neutral and raised its price target to $77 from $63 to reflect reduced consensus expectations and industry consolidation. The analyst said two large-scale Clinical transactions announced over the past month reinforce his view of consolidation in the CRO space and reduced downside risk for Parexel.
05/23/17
05/23/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Overweight from Neutral at JPMorgan with analyst Lisa Gill saying she believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted. 2. Aegion (AEGN) upgraded to Buy from Hold at Craig-Hallum with analyst Eric Stine saying the recent pullback provides an attractive opportunity to own a "high-quality company" with positive trends across much of its business. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Karen Holthouse saying there is upside to her $36 price target. Holthouse believes Wingstop is well positioned for digital ordering and off-premise tailwinds and expects an acceleration in same-store-sales driven by national advertising momentum. 4. Parexel (PRXL) upgraded to Neutral from Sell at Goldman Sachs with analyst Robert Jones citing reduced consensus expectations and industry consolidation. 5. On Deck Capital (ONDK) upgraded to Outperform from Market Perform at FBR Capital with analyst Bob Ramsey saying he believes the company's path to profitability creates "significant" upside for the shares over the next 12 months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/17
EVER
06/20/17
DOWNGRADE
EVER
In Line
Parexel downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Parexel following the acquisition by Pamplona for $88.10 per share.
CMG Chipotle

06/20/17
DBAB
06/20/17
NO CHANGE
Target $300
DBAB
Sell
Chipotle margin recovery remains under pressure,' says Deutsche Bank
Deutsche Bank analyst Brett Levy says Chipotle Mexican Grill's costs continue to weigh on unit-level performance after management last night explained certain unit-level costs in a regulatory filing. Elevated food costs, incremental marketing spending and other operating expenses continue to weigh on restaurant-level profits, Levy tells investors in a research note. He lowered his Q2 earnings per share estimate by 20c to $2.04 and keeps a Sell rating on Chipotle.
06/20/17
FBCO
06/20/17
NO CHANGE
Target $425
FBCO
Neutral
Chipotle estimates lowered at Credit Suisse after guidance
Credit Suisse analyst Jason West noted that Chipotle's updated guidance on Q2 food costs and other operating expenses was unfavorable and he cut his Q2 earnings forecast to well-below consensus at $2.00 per share. West maintains his Neutral rating and $425 price target on Chipotle shares.
06/20/17
MAXM
06/20/17
NO CHANGE
Target $440
MAXM
Hold
Chipotle estimates reduced after cost comments at Maxim
Maxim analyst Stephen Anderson noted that Chipotle management alluded to higher costs incurred during the quarter in commentary released ahead of the company's planned presentations at investor conferences this week. Given the new guidance, Anderson lowered his earnings estimate for Q2, though he maintains his expectations for a double-digit comparable sales increase. The analyst keeps a Hold rating and $440 price target on Chipotle shares.
06/20/17
NOMU
06/20/17
NO CHANGE
Target $480
NOMU
Neutral
Chipotle price target lowered to $480 from $510 at Nomura Instinet
Nomura Instinet analyst Mark Kalinowski lowered Chipotle's price target to $480 from $510 following management commentary that indicates margin pressure in Q2. Management now expects Q2 other operating costs to be higher than in Q1, contributing to the analyst's reduction in 2017 earnings estimate to $8.30 from $8.75, and 2018 earnings estimate to $12 from $12.75. Kalinowski rates Chipotle an Equal Weight.
FDUS Fidus Investment
$17.25

0.17 (1.00%)

09/22/16
DADA
09/22/16
INITIATION
Target $17
DADA
Buy
Fidus Investment initiated with a Buy at DA Davidson
Target $17.
01/09/17
BARD
01/09/17
DOWNGRADE
BARD
Neutral
Fidus Investment downgraded to Neutral from Outperform at Baird
01/09/17
BARD
01/09/17
DOWNGRADE
Target $17
BARD
Neutral
Fidus Investment downgraded to Neutral at Baird
As previously reported, Baird analyst Bryce Rowe downgraded Fidus Investment to Neutral from Outperform. The analyst said he sees limited upside from his price target. Rowe maintained his $17 price target on Fidus Investment shares.
01/10/17
KBWI
01/10/17
INITIATION
Target $17
KBWI
Market Perform
Fidus Investment initiated with a Market Perform at Keefe Bruyette
Keefe Bruyette analyst Ryan Lynch started Fidus Investment with a Market Perform rating and $17 price target.
ADP ADP
$104.11

0.62 (0.60%)

06/20/17
GSCO
06/20/17
DOWNGRADE
Target $64
GSCO
Neutral
Paychex downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst James Schneider downgraded Paychex (PAYX) to Neutral citing delayed macro catalysts. Tax reform is likely delayed until 2018 and may come at smaller scale, Schneider tells investors in a research note. The analyst expects the company's FY18 revenue growth "will remain muted." He lowered his price target for Paychex shares to $64 from $68. Schneider this morning also downgraded ADP (ADP) to Neutral from Conviction Buy.
06/20/17
GSCO
06/20/17
DOWNGRADE
Target $105
GSCO
Neutral
ADP downgraded to Neutral from Conviction Buy at Goldman Sachs
Goldman Sachs analyst James Schneider downgraded ADP to Neutral from Conviction Buy citing delayed macro catalysts. Tax reform is likely delayed until 2018 and may come at smaller scale, Schneider tells investors in a research note. The analyst also expects upside from higher interest rates to play out more slowly. He lowered his price target for ADP shares to $108 from $115.
06/02/17
06/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ADP (ADP) downgraded to Underperform from In Line at Evercore ISI with analyst David Togut saying the firm's Payroll Manager Survey indicates softer demand and rising client losses at ADP. 2. Workday (WDAY) downgraded to Neutral from Buy at BTIG with analyst Joel Fishbein saying the company reported a "good" quarter, but high expectations are reflected in valuation. 3. Analog Devices (ADI) downgraded to Reduce from Neutral at Nomura Instinet with analyst Romit Shah saying he believes shares are overvalued and the Street may be too optimistic about the quality of Analog's franchise saying third quarter guidance was "very mixed" and implies the company missed on margins, a key part of the bull case. 4. Take-Two (TTWO) downgraded to Underperform from Neutral at Hilliard Lyons with analyst Jeffrey Thomison citing valuation. 5. Range Resources (RRC) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Brian Singer saying shares have underperformed since being added to the list on October 31, 2016 on the back of poor gas sentiment and reduced confidence in Louisiana assets acquired in 2016 due to unfavorable well performance and a shift in how the company plans to flow future wells. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/17
EVER
06/01/17
DOWNGRADE
EVER
Underperform
ADP downgraded to Underperform from In Line at Evercore ISI
Evercore ISI analyst David Togut said the firm's Payroll Manager Survey indicates softer demand and rising client losses at ADP. As a result, Togut downgraded ADP to Underperform from Neutral and cut his price target to $85 from $95. The analyst said customer satisfaction at ADP has declined slightly and ACA spending, which drove ADP's bookings strength over the last two years, is now complete. Togut believes ADP's FY18 revenue growth could be as low as 2%, versus consensus of 6%, and expects earnings to be flat at $3.70, versus consensus of $3.98.

TODAY'S FREE FLY STORIES

KMX

CarMax

$68.84

0.17 (0.25%)

, FINL

Finish Line

$9.22

-0.21 (-2.23%)

20:25
09/21/17
09/21
20:25
09/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMX

CarMax

$68.84

0.17 (0.25%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:47
09/21/17
09/21
18:47
09/21/17
18:47
Periodicals
HP Enterprise planning approximately 5,000 job cuts, Bloomberg reports »

In part of a broader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

RP

RealPage

$39.35

-0.1 (-0.25%)

18:41
09/21/17
09/21
18:41
09/21/17
18:41
Hot Stocks
RealPage expects $3M-$4M of renter's insurance claims from hurricanes »

RealPage announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:39
09/21/17
09/21
18:39
09/21/17
18:39
Periodicals
Breaking Periodicals news story on HP Enterprise »

HP Enterprise planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

YUM

Yum! Brands

$76.48

0.11 (0.14%)

18:37
09/21/17
09/21
18:37
09/21/17
18:37
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MAR

Marriott

$107.57

-0.12 (-0.11%)

18:32
09/21/17
09/21
18:32
09/21/17
18:32
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ESPGY

Esprit Holdings

$1.21

0.018 (1.51%)

18:29
09/21/17
09/21
18:29
09/21/17
18:29
Conference/Events
Esprit Holdings management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BA

Boeing

$256.04

0.58 (0.23%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Hot Stocks
Boeing: Turkish Airlines announces intent to order 40 787-9 Dreamliners »

Boeing and Turkish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

M

Macy's

$21.16

-0.32 (-1.49%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Conference/Events
Macy's management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TAHO

Tahoe Resources

$5.60

0.02 (0.36%)

18:12
09/21/17
09/21
18:12
09/21/17
18:12
Hot Stocks
Tahoe Resources raises 2017 gold operations view to 400K-500K »

Tahoe Resources updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$18.42

0.02 (0.11%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Conference/Events
Atkore management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Sep

FTR

Frontier Communications

$11.69

-0.31 (-2.58%)

18:10
09/21/17
09/21
18:10
09/21/17
18:10
Hot Stocks
Frontier Communications operations in Florida return to near-normal levels »

Daily operations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.66

-0.06 (-0.56%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Playa Hotels & Resorts reports no significant damage from Maria »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint »

Shares of Ascendis Pharma…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$103.90

-0.04 (-0.04%)

18:04
09/21/17
09/21
18:04
09/21/17
18:04
Hot Stocks
Celanese increases price of acetyl intermediates »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNOW

NOW Inc.

$12.98

0.1 (0.78%)

18:03
09/21/17
09/21
18:03
09/21/17
18:03
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

JOBS

51job

$58.50

0.01 (0.02%)

18:02
09/21/17
09/21
18:02
09/21/17
18:02
Hot Stocks
51job announces strategic investment in Lagou »

51job announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$43.63

0.17 (0.39%)

17:53
09/21/17
09/21
17:53
09/21/17
17:53
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

APC

Anadarko

$48.49

3.68 (8.21%)

17:43
09/21/17
09/21
17:43
09/21/17
17:43
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko buyback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

HCC

Warrior Met Coal

$23.28

-1.05 (-4.32%)

17:42
09/21/17
09/21
17:42
09/21/17
17:42
Hot Stocks
Warrior Met Coal receives favorable IRS private letter ruling »

Warrior Met Coal reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$107.27

-0.03 (-0.03%)

17:35
09/21/17
09/21
17:35
09/21/17
17:35
Hot Stocks
MAA announces estimated impact of Hurricanes Irma and Harvey »

MAA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$280.42

0.38 (0.14%)

17:31
09/21/17
09/21
17:31
09/21/17
17:31
Hot Stocks
Northrop Grumman awarded $124.7M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$205.72

1.45 (0.71%)

17:29
09/21/17
09/21
17:29
09/21/17
17:29
Hot Stocks
General Dynamics Electric Boat awarded $5B government contract »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.